Get our introductory offer at only
$0
.99*/month
Cancel anytime
*$0.99/month for first 3 months
$29.90/month for the next 9 months
You are here
China biotech's 'coming-out party' masks long road ahead as innovation still lacking
An under-developed academic ecosystem and a preoccupation with generic drugs are also obstacles
China contributes just 4% of global drug innovation - as measured by the number of products in development and recent launches - against 50% from the United States, according to an October 2016 report from four Chinese pharmaceutical associations.
PHOTO: REUTERS
Shanghai
INVESTORS are betting on China's potential to feed the global pharmaceutical pipeline, putting a multibillion-dollar price tag on a handful of stocks, even as the country struggles to close a huge R&D gap with the West.
Shares in firms such as Chi-Med, Beigene and Zai...
If you are already a BT subscriber, please log in.
